Complete Genomics, the low-cost gene sequencing company in Mountain View, CA, has set a goal of pricing 6 million shares in its initial public offering at a price of $12 to $14, according to a filing today with the Securities and Exchange Commission. If the company can find demand from investors at the top of its range, and its underwriters buy an extra 900,000 shares, then the deal could bring in as much as $96.6 million. The company is scheduled to set the actual IPO price the week of Nov. 8, according to Renaissance Capital. Complete Genomics’ existing roster of investors includes OrbiMed Advisors, Essex Woodland Health Ventures, San Diego-based Enterprise Partners Venture Capital, Kirkland, WA-based OVP Venture Partners, and Palo Alto, CA-based Prospect Venture Partners. The company plans to begin trading under the symbol (NASDAQ: [[ticker:GNOM]]).
